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Abstract
Background Trivalent influenza vaccines encompass one
influenza B lineage; however, predictions have been
unreliable on which of two antigenically distinct circulat-
ing lineages will dominate. Quadrivalent seasonal influenza
vaccines contain strains from both lineages. This analysis
assesses the cost effectiveness of switching from trivalent
inactivated influenza vaccination (TIV) in Finland to
quadrivalent vaccination, using inactivated (QIV) or live-
attenuated (Q-LAIV) vaccines.
Methods A transmission model simulated the dynamics of
influenza infection while accounting for indirect (herd)
protection. Prior distributions for key transmission param-
eters were repeatedly sampled and simulations that fitted
the available information on influenza in Finland were
recorded. The resulting posterior parameter distributions
were used in a probabilistic sensitivity analysis in which
economic parameters were sampled, simultaneously
encompassing uncertainty in the transmission and eco-
nomic parameters. The cost effectiveness of a range of
trivalent and quadrivalent vaccine policies over a 20-year
time horizon was assessed from both a societal and payer
perspective in 2014 Euros.
Results The simulated temporal incidence pattern of
symptomatic infections corresponded well with case
surveillance data. A switch from the current TIV to
Q-LAIV in children (2 to\18 years) and to QIV in other
ages was estimated to annually avert approximately 76,100
symptomatic infections (95 % range 36,700–146,700),
11,500 primary care consultations (6100–20,000), 540
hospitalisations (240–1180), and 72 deaths (32–160), and
was cost-saving relative to TIV (€374 million averted
[€161–€752], in 2014 Euros, discounted at 3 %). This
scenario had the highest probability of being the most cost-
effective scenario considered.
Conclusions This analysis demonstrates that quadrivalent
vaccination is expected to be highly cost effective, reduc-
ing the burden of influenza-related disease.
Key Points
Dynamic transmission model incorporating indirect
(herd) protection.
Probabilistic model, calibrated to data,
simultaneously accounts for uncertainty in
transmission, clinical and economic parameters.
Costs and quality-adjusted life-years of various
influenza vaccination scenarios in Finland were
compared.
A quadrivalent scenario, with live-attenuated vaccine
in children 2 to\18 years of age, was the scenario
with the highest expected net benefit.
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The significant annual health and economic burden of
influenza has prompted a number of studies to assess
potentially more effective and cost-effective ways of con-
trolling this infection [1–5].
Evidence is accumulating that paediatric influenza vac-
cination is an efficient and cost-effective approach to alle-
viating the burden of influenza in children, as well as in the
wider population [2, 3]. Finland was one of the first coun-
tries to implement routine paediatric influenza vaccination
[6] and currently recommends immunising all children
between the ages of 6 and 35 months, in addition to seniors
65 years or older and persons of any age over 36 months at
increased risk of influenza-related complications.
The co-circulation, since 2002 [7], of two genetic lin-
eages of influenza B (Yamagata and Victoria) has promp-
ted a move away from the use of trivalent vaccines,
containing antigens to two influenza A strains (one from
each of the currently circulating subtypes, AH1N1 and
AH3N2) and one influenza B lineage strain, to a vaccine
containing antigens to all four strains. These quadrivalent
vaccines avoid the need to predict which B lineage will
circulate in the following influenza season, a prediction
that has been correct in only four of the ten seasons after
Victoria first circulated in Finland. In three other seasons,
either both influenza B strains circulated or the selected
strain showed only sporadic incidence. In three seasons, the
wrong strain was selected [7–9]. This situation is not
unique to Finland, with mismatch years occurring wherever
trivalent vaccines are used [4, 10].
Several studies looking to estimate the public health and
economic impact of switching from a trivalent to a
quadrivalent seasonal influenza vaccine have used a static
modelling approach with retrospective data to study health
outcomes [11, 12]. Static models are unable to account for
dynamic changes in the probability of infection and hence
these studies failed to account for indirect protection and,
as a result, may underestimate the impact of vaccination.
Current recommended practice [13] is to use a dynamic
model when evaluating infectious disease interventions
that are likely to have an impact on transmission. Few other
published studies to date have taken transmission dynamics
into account when comparing the effects of trivalent and
quadrivalent vaccination on seasonal influenza [5, 14, 15].
This paper uses a dynamic transmission model to
examine the efficacy and cost-utility of nationally replacing
currently used trivalent influenza vaccines in Finland with
quadrivalent vaccines, either inactivated or live-attenuated.
This model uses a probabilistic sensitivity analysis (PSA)
approach to take into account the uncertainty in the
transmission, clinical and economic parameters.
2 Methods
A compartmental transmission model was used to simulate
the population-level dynamics of influenza infection (Sect.
2.1). A set of key transmission parameters was repeatedly
sampled from input distributions and the transmission
model was numerically integrated; those sets whose results
fit the available information on influenza in Finland were
retained, thus calibrating the model (Sect. 2.2). A set of
updated transmission parameter distributions was thus
obtained, and the transmission model was integrated with
these parameter sets, to produce a PSA of the transmission
model inputs. The results of integrating the model with
these parameters were used as inputs to an economic PSA
in which the clinical and economic parameters were sam-
pled (Sect. 2.3). The model therefore simultaneously
encompassed uncertainty in the transmission parameters in
addition to the economic inputs.
2.1 Dynamic Transmission Model
The dynamic transmission model had an SEIRS(V) struc-
ture [16] (Susceptible, Exposed, Infectious, Recovered,
Vaccinated), stratified by age in months (see the electronic
supplementary material, which provides details and equa-
tions). Ageing was simulated on a monthly basis, with
population [17] and lifetable [18] data informing the
demographics. Individuals within an age group were
assumed to mix at random. Estimates of the relative rate of
contact between individuals in the same and in disparate
age groups were derived from the POLYMOD study [19]
and recorded in a contact matrix. The product of these age-
specific contact rates and the per contact probability of
transmission yielded an age-stratified matrix of transmis-
sion coefficients. The magnitude of these transmission
coefficients was assumed to vary sinusoidally over time to
reflect the observed seasonality in influenza transmission.
Imported influenza infections were seeded into the model
each autumn. Vaccination was assumed to confer imme-
diate protection and to have been completed prior to the
start of the influenza season, being applied on 1 September
each year.
Four influenza viruses were assumed to circulate:
AH1N1, AH3N2, B Yamagata, and B Victoria; the model
assumed no cross-protection between these viruses. Within
each subtype or lineage, influenza strains were not distin-
guished. The waning of immunity over time, whether
naturally-acquired or vaccine-induced, simulated a com-
bination of antigenic drift and the waning of immunity with
age. The annual vaccine strain composition was obtained
from World Health Organization (WHO) recommendations
[20].
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The pre-existing immunity structure (proportion of the
population immune, by age and virus) at the start of the
model was estimated by running the model forward, using
previously published parameter inputs [21] adapted for
Finland’s population size, to estimate the susceptible
population by age at the start of an influenza season (see
the electronic supplementary methods for details).
2.2 Model Calibration
The model was calibrated to observed data on the incidence
of symptomatic influenza infection in children [22].
Resulting parameter combinations were thus consistent
with this observed epidemiology. In the calibration, the
transmission inputs underwent Monte Carlo sampling fol-
lowed by numerical integration of the model from the
2000/2001 to 2008/2009 seasons. The resulting simulated
influenza incidence was compared with epidemiological
data from the same period, using a set of defined fit criteria.
To do so, the incidence of infection was converted to that
of symptomatic infections by applying the conditional
probability of influenza symptoms, given that infection had
occurred (described in the electronic supplementary
methods).
2.2.1 Data
Data used to calibrate the model were estimates of the
incidence of symptomatic influenza infection in children
from Turku, Finland, over the 2000/2001 and 2001/2002
seasons [22]. WHO [23] surveillance reports provided an
indication of the pre-pandemic temporal variation in
influenza incidence.
Finnish National Institute for Health and Welfare (THL)
[8] surveillance reports were used as an independent check
of the temporal pattern of variation in incidence in the
calibrated model; in order to compare the variation in
incidence published in these reports with that simulated by
the model, on the same scale, the two datasets were each
normalised by dividing through by their respective overall
mean incidence.
These data and the process of normalisation are
described in more detail in the electronic supplementary
methods.
2.2.2 Probabilistic Sampling
Key inputs are summarized in Table 1. Sets of transmission
parameters were drawn from assigned input distributions.
If the corresponding simulated incidence of symptomatic
infection, for each virus separately, met the following
heuristic criteria, the simulation was retained:
I. (a) AH1N1, AH3N2, and B Yamagata: Fell within a
predefined deviance of the Turku data [22] (20 for
H1N1 and Yamagata, 150 for H3N2). Deviance was
calculated as the sum of the individual Poission
deviances between model and data for each age group
and each season over 2000/2001 to 2001/2002 (see the
electronic supplementary methods for further details).
(b) B Victoria: When introduced in 2002/2003, the
cumulative seasonal incidence in that season fell within
a range consistent with seasonal influenza [7].
II. Ratio of standard deviation/mean cumulative seasonal
incidence for each virus within the range of the same
measure as derived from WHO surveillance data [23].
III. A low incidence prior to the usual start of the
influenza season in week 40 (less than approximately
1 % of the population).
The B Yamagata lineage was calibrated first, with all
transmission inputs sampled. Parameters were assumed to
be common across influenza strains unless there was suf-
ficient information to assume otherwise. Common param-
eters were not resampled in the subsequent calibration of
the other strains. A lack of detailed data for the Victoria
lineage meant that all parameters were set equal to those of
the corresponding Yamagata simulation, except for vaccine
efficacy and a virus-specific scale factor applied to the pre-
Table 1 Key transmission model inputs
Input Minimum Maximum Sampling distribution Stratified by
R0 parameters
Transmission coefficient 1.25E-07 3.75E-07 Uniform Virusa
Latent period (days) 0.01 3 Uniform Virusa
Infectious period (days) 0.5 5 Uniform Virusa
Immunity parameters
Duration of naturally-acquired immunity (years) 0.5 75 Uniform Virusa
Duration of vaccine-induced immunity (years) 0.5 3 Uniform Virusa
Pre-existing immunity See Fig. S1.2 in the electronic supplementary methods Virus
a B Victoria inputs were set equal to B Yamagata samples for each simulation
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existing immunity age profile. For each influenza A sub-
type, efficacy and the pre-existing immunity scale factor
were also resampled, as well as the transmission coeffi-
cient, infectious period, latent period, and durations of
immunity (naturally-acquired and vaccine-induced). A
detailed list of these inputs and their distributions is pro-
vided in the electronic supplementary methods.
The model was calibrated over the first two seasons
(2000/2001 to 2001/2002), and each set of parameter
samples whose results met the heuristic criteria above was
retained; the group of all these sets of parameter samples
was collectively referred to as the calibrated model.
The transmission model simulated the dynamics of
influenza infection, irrespective of clinical presentation
(symptomatic or asymptomatic). During calibration, the
probability of symptoms, given influenza infection, was
also sampled for each run in order to calibrate the cumu-
lative seasonal incidence of each strain to the symptomatic
infection data [22] for that season. All four viruses were
assumed to be equally likely to produce symptoms.
For each parameter set in the calibrated model, the
model was then run from 2000/2001 to 2008/2009. The
resulting cumulative seasonal incidences were aggregated
over all four strains to yield the seasonal incidence of total
symptomatic influenza, and subsequently averaged over all
seasons and all simulations to produce the expected (mean)
seasonal incidence for use in the following risk function
calculations.
2.2.3 Clinical Outcomes and Risk Functions
Age-stratified risk functions translated symptomatic infec-
tions into primary care physician consultations, hospitali-
sations, and deaths.
Finnish estimates were obtained for the mean annual
number of influenza-attributable hospitalisations in chil-
dren [24] and deaths in all ages [25]. These age-stratified
estimates were divided by the age-stratified expected sea-
sonal incidence of symptomatic infections to obtain the
age-stratified probability of an outcome, given the influ-
enza symptoms. These probabilities were not stratified by
influenza strain due to a lack of available data to indicate
variation by strain.
Age-stratified risk functions (probabilities of an out-
come, given the symptoms) for hospitalisations in adults,
and for general practitioner (GP) consultations in all ages,
were based on estimates from a previous adaptation of this
model for the UK [21, 26].
2.3 Expected Net Benefit Analysis
In this analysis, risk functions and economic estimates
were applied to the calibrated model output to calculate
clinical and economic outcomes, which were then com-
pared for six vaccination scenarios described below.
Each parameter set obtained by the calibration was
reused once and the model was again integrated from the
2000/2001 season, and then projected past 2014 over a
20-year time horizon. The risk functions and clinical and
economic parameters were then sampled in a Monte Carlo
simulation and applied to the transmission results.
2.3.1 Vaccination
Key vaccination inputs are reported in Table 2 and Fig. 1.
2.3.1.1 Scenarios For each set of transmission parameter
samples obtained during the calibration process, six vac-
cination scenarios were run (Table 3). These were chosen
in order to explore the cost effectiveness of switching from
the currently used trivalent inactivated influenza vaccine
(TIV) to the quadrivalent equivalent (QIV), and then the
potential cost effectiveness of replacing QIV with a
quadrivalent live-attenuated influenza vaccine (Q-LAIV) in
those age groups in which it is licensed (children aged 2
to\18 years). Complete replacement of QIV with Q-LAIV
over this age range was analysed, in addition to an equal
market split between QIV and Q-LAIV in these children. In
order to be able to quantify the value of current treatment, a
scenario without vaccination was also included.
These scenarios followed the status quo until diverg-
ing in the 2014/2015 season, with the exception of the
scenario without vaccination, in which there was no
vaccination from the 2000/2001 season onwards. The
strain composition of trivalent vaccines was obtained
from WHO recommendations [20] up to and including
the 2013/2014 season. In scenarios with quadrivalent
vaccination, all relevant vaccines were assumed to
Table 2 Key vaccination inputs
Age group (years) Inactivated Live
Mean 95 % CI Mean 95 % CI
Vaccine efficacy
0 to\18 [36] 48 31–61 80 70–87
18 to\65 [36] 59 50–66 39a 16–55
65? [47] 50 39–59 – –
Vaccine dosage costsb
0 to\65 7.18 – 25.75a –
65? 7.05 – – –
CI confidence interval, PSA probabilistic sensitivity analysis
a Live-attenuated vaccine had 0 % market share in those aged C18
years in all modelled scenarios
b Dosage costs were held fixed in the PSA; assumptions were con-
sidered in sensitivity analyses (Sect. 2.3.3)
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entirely switch to quadrivalent during 2014. Trivalent
scenarios followed a random pattern, consistent with the
observed 50 % probability of a trivalent vaccine match to
the circulating strain of influenza B, from the 2014/2015
season onwards to determine which influenza B lineage
was included in the vaccine. For scenarios in which live-
attenuated vaccine was modelled in children, the switch
was also assumed to occur entirely during the 2014/15
season.
The 50 and 100 % in some scenario names refer to the
proportion of administered vaccines that were live-attenu-
ated, and have no relation to the influenza vaccine uptake
in the scenario.
2.3.1.2 Uptake Where possible, vaccine uptake prior to
the 2012/13 season was based on data, with any unknown
quantities over this period sampled in the calibration. An
online survey was carried out from a nationally represen-
tative register of respondents, based on members of the
general public, to estimate the vaccination uptake in Fin-
land, by age, in the 2012/2013 season (Fig. 1). The
resulting estimates were applied in all age groups from
2012/2013 onwards, sampled within confidence limits. For
a given simulation, all vaccination scenarios used the same
sampled uptake value.
Details of both the survey and the probabilistic sampling
of both the initial vaccination and the survey estimates are
described in the electronic supplementary methods.
2.3.2 Clinical and Economic Outcomes
For each model simulation, the cumulative age-stratified
numbers of symptomatic infections were recorded from
mid-2014 to mid-2034, both undiscounted and discounted
at 3 % [27] from the start of the 2014/2015 influenza
season. The risk functions were applied to these cumulative
estimates to obtain clinical outcomes; estimated costs and
quality-adjusted life-years (QALYs) lost were then applied
to these outcomes.
Price parity between trivalent and quadrivalent vaccines
(TIV = QIV and LAIV = Q-LAIV) was assumed. Costs
were split into direct medical costs, direct travel costs, and
indirect productivity costs, which included the opportunity
costs of absenteeism, caring for an ill child, time to attend a
vaccination appointment, and the (human capital) produc-
tivity costs foregone due to premature death. Costs were
obtained from national reports [28], price lists [29], and
previous cost-effectiveness analyses [3], inflated to 2014
values (first quarter) using price and salary indices [30, 31].
Productivity costs were calculated, and costs are presented
from both a societal and payer perspective [32].
A QALY loss due to morbidity [33] was applied to each
modelled symptomatic infection, and age-specific QALYs
[34] lost were applied to each influenza-attributable pre-
mature death [34].
The base-case analysis was obtained by averaging the
clinical and economic outputs over all simulations. The
ranges in which 95 % of simulation outputs fell were also
calculated for each outcome.
A set of cost-effectiveness acceptability curves was
calculated to illustrate the probability of each scenario
being cost effective over a range of cost-effectiveness
thresholds. As the objective of most health policies is to
maximise health, a cost-effectiveness acceptability frontier
was also derived, which illustrates the probability that the
Fig. 1 Vaccine uptake, from a TNS Gallup Oy survey, sampled in
the probabilistic sensitivity analysis
Table 3 Vaccination scenarios
Scenario name Description
No vaccination No vaccination in any age, from 2000/2001 and for the entire model run
TIV Status quo: TIV in individuals 6 months of age and over
QIV QIV, 6 months and older
TIV/Q-LAIV (100 %) TIV, 6 to\24 months and 18? years; Q-LAIV, 2 to\18 years (100 % market share)
QIV/Q-LAIV (50 %) QIV, 6 to\24 months and 18? years; Q-LAIV and QIV, 2 to\18 years (50 % market share each)
QIV/Q-LAIV (100 %) QIV, 6 to\24 months and 18? years; Q-LAIV, 2 to\18 years (100 % market share)
TIV trivalent inactivated vaccine, QIV quadrivalent inactivated vaccine, Q-LAIV quadrivalent live-attenuated influenza vaccine
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scenario with the highest expected net health benefit
(ENHB) is cost effective [35].
2.3.3 Sensitivity Analyses
A univariate sensitivity analysis was run to explore the
sensitivity of the model results to an increase or decrease of
10 % in key parameter values. The overall mixing matrix
structure could not be altered in the univariate analysis,
therefore a sensitivity analysis was also run directly on this
structure. Dosage cost assumptions (price parity and list
prices) were tested, and a break-even analysis compared
dosage prices for select scenarios. The structural assump-
tion of density- versus frequency-dependent forces of
infection was considered by comparing both methods (see
the electronic supplementary methods and results for
details).
In its entirety, the model was run as a PSA on the
transmission, clinical and economic parameters. This
approach bolstered the robustness of the results and
decreased the need, seen in prior models [21], for scenario
or extreme value analyses to help quantify the uncertainty
in the transmission model results.
3 Results
3.1 Calibration
Of approximately 13,000,000 parameter samples, 8998
simulations were amassed that fit the heuristic criteria (I)–
(III).
An encouragingly close correspondence was achieved
between the normalised monthly incidence of symptomatic
infection output by the model and the normalised THL case
surveillance data [8] (Fig. 2). Although the model was only
calibrated to (non-THL) data [22] from the 2000/2001 and
2001/2002 seasons, this figure shows that the observed
incidence of infection was similar to the average model
incidence of infection, and was encompassed by the upper
limit of the 95 % range of the calibrated model in nearly all
pre-pandemic seasons. Direct comparison between the
model average and the THL data must be undertaken with
caution as the average over all calibrated model runs will
show far less variation than the results of individual
parameter sets in the calibrated model. Additionally, the
THL surveillance data are themselves an estimate of the
true incidence. The relative incidence of influenza A and B
is also similar between the THL data and the model out-
comes, even though this ratio was not one of the model fit
heuristics. The correspondence is encouraging as these
THL data were only used for validation and not for the
calibration of the model.
Sampling from uniform input distributions, and keeping
the samples that met the calibration criteria, produced
clearly defined unimodal distributions (Fig. 3) for the basic
reproduction number (the number of secondary infections
produced by an average primary infection in a totally
susceptible population, R0); these distributions were clearly
updated from their initial inputs by the acceptance–rejec-
tion sampling according to the calibration heuristic
(Fig. 4). Other updated parameter distributions are reported
in the electronic supplementary results.
3.2 Clinical Outcomes
The undiscounted clinical outcomes predicted by the model
were averaged over all simulations to give the expected
average annual clinical burden of influenza in Finland over
the 20-year time horizon of the model; these outcomes are
summarised in Table 4. The expected values are presented,
along with ranges, which represent the intervals in which
95 % of the 8998 simulations fell.
On average, a switch from the current trivalent inacti-
vated vaccines to QIVs was estimated to annually avert
40,500 symptomatic infections (95 % range
15,700–98,400), 6100 primary care physician consultations
(2700–13,300), 360 hospitalisations (140–940) and 54
deaths (22–135).
Fig. 2 Monthly incidence of symptomatic influenza, averaged over
all runs and normalised to the 2000/2001 to 2007/2008 overall
average. Comparison of the normalised modelled monthly incidence
of symptomatic influenza infection to normalised National Institute
for Health and Welfare (THL) surveillance reports [8] of symptomatic
influenza. Figure derived from THL data, with permission
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Due to the higher efficacy, by strain, of live-attenuated
vaccination in children [36], using exclusively Q-LAIV in
children 2 to\18 years of age rather than exclusively
using QIV in everyone aged 6 months and over was esti-
mated to avert, on average, an additional 35,600 symp-
tomatic infections (16,400–64,000), 5300 primary care
Fig. 3 Distribution of parameter samples over 8998 runs: calibrated distributions, by virus, of selected parameters contributing to the basic
reproduction number (R0) and resultant R0 distributions
Fig. 4 Distribution of basic
reproduction number (R0)
parameter samples over 8998
runs: comparison between
initial input distributions and
updated (calibrated)
distributions, by virus
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consultations (2800–8800), 170 hospitalisations (70–345),
and 18 deaths (6–38) (Table 4).
Switching from TIV to TIV/Q-LAIV 100 % is expected
to annually avert, on average, 55,000 symptomatic infec-
tions (95 % range 29,000–92,000), 8500 GP consultations
(5000–13,500), 300 hospitalisations (150–550) and 35
deaths (17–65).
3.3 Economic Outcomes
The 20-year cumulative discounted total costs and QALY
losses, calculated for each scenario as the expectation over
all simulation runs, are summarised in Table 5. From a
societal perspective, from QIV downwards, each succes-
sive scenario in Table 5 has lower total costs and fewer
QALYs lost than the preceding scenario; each scenario
dominates the previous, with the QIV/Q-LAIV 100 %
scenario dominating all. All scenarios were expected to be
cost saving from a societal perspective compared with no
vaccination (Table 5), with the exception of the purely TIV
scenario (status quo) which, although not cost saving, is
nevertheless likely to be cost effective.
From a payer perspective, the TIV and TIV/Q-LAIV
100 % scenarios were still dominated (Table 5). The
remaining scenarios are all likely to be considered cost
effective compared with no vaccination, and, in particular,
Table 4 Undiscounted 20-year average annual number of clinical outcomes in Finland
Scenario Symptomatic infections GP consultations Hospitalisations Deaths
Exp (range) Ratea Exp (range) Ratea Exp (range) Ratea Exp (range) Ratea
No vaccination 461,658 (251,158–796,580) 8724 62,139 (35,731–104,489) 1174 3758 (1553–7374) 71 516 (213–997) 9.7
TIV 357,454 (205,615–581,248) 6755 46,839 (27,820–74,934) 885 2276 (988–4459) 43 292 (126–559) 5.5
QIV 316,988 (170,321–531,924) 5990 40,702 (22,538–67,269) 769 1913 (745–3897) 36 238 (90–476) 4.5
TIV/Q-LAIV
100 %
302,515 (152,172–516,418) 5716 38,193 (19,608–65,024) 722 1972 (732–4066) 37 257 (95–517) 4.8
QIV/Q-LAIV
50 %
298,779 (151,774–511,376) 5646 37,948 (19,856–63,905) 717 1826 (668–3788) 34 229 (82–464) 4.3
QIV/Q-LAIV
100 %
281,389 (135,239–490,111) 5317 35,361 (17,372–60,708) 668 1741 (600–3677) 33 220 (75–455) 4.2
Scenario names are defined in Table 3
GP general practitioner, TIV trivalent inactivated vaccine, QIV quadrivalent inactivated vaccine, Q-LAIV quadrivalent live-attenuated influenza
vaccine, Exp expectation (average) over all simulations, range range in which 95 % of simulations lay
a Rate/100,000 person years












No vaccination 2828 159
TIV 3066 112 Dominated
QIV 2795 97 Dominated
TIV/Q-LAIV 100 % 2717 94 Dominated
QIV/Q-LAIV 50 % 2692 91 Dominated
QIV/Q-LAIV 100 % 2598 86 -229 73 Cost-saving
Payer perspective
No vaccination 230 159
TIV 580 112 Dominated
QIV 556 97 327 62.4 5237
TIV/Q-LAIV 100 % 628 94 Dominated
QIV/Q-LAIV 50 % 586 91 30 5.5 5329
QIV/Q-LAIV 100 % 616 86 30 5.2 5734
Scenario names are defined in Table 3. Please see Table S2.2 in the electronic supplementary results for a breakdown of the costs and QALYs
TIV trivalent inactivated vaccine, QIV quadrivalent inactivated vaccine, Q-LAIV quadrivalent live-attenuated influenza vaccine, QALY quality-
adjusted life-year, ICER incremental cost-effectiveness ratio, DCosts, DQALYS incremental versus preceding non-dominated scenario
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the QIV/Q-LAIV 100 % scenario was the most cost
effective in the base case.
On average, the 20-year cumulative discounted saving
of switching from the purely TIV scenario to the QIV/Q-
LAIV 100 % scenario was estimated to be €468 million
(including productivity costs) and 26,000 QALYs. The
uncertainty around these estimates is considerable (95 %
range of simulations €206 million–€890 million and
11,100–53,900 QALYS); however, the trend in the
expected (mean) values is clear (Fig. 5).
From a societal perspective, the scenario in which
Q-LAIV is used exclusively in 2- to\18-year-olds had the
highest probability of being the most cost-effective sce-
nario, and yielded the highest ENHB at any cost-effec-
tiveness threshold (Fig. 6).
Productivity costs represented the majority of the cost
burden of influenza (see Table S2.2 in the electronic sup-
plementary results). When productivity costs were exclu-
ded from the model, the scenario in which Q-LAIV had
100 % market share in 2- to\18-year-olds had the highest
ENHB at thresholds above €6000/QALY, and also had the
highest probability of being cost effective at thresholds
above €6600/QALY (Fig. 6).
3.4 Sensitivity Analyses
In the univariate sensitivity analysis, those parameters
having a direct effect on the basic reproductive number
(transmission coefficient, infectious period) had the great-
est influence on the cost effectiveness of individual sce-
narios. Of those factors that can be most easily changed in
practice, dosage price had the greatest influence on costs
and QALYs. Relatively large dosage price increases,
dependent on the threshold chosen, were possible before
the QIV/Q-LAIV 100 % scenario became less preferable in
a pairwise comparison with QIV; the same was true of QIV
compared with TIV. In all dosage price assumption sensi-
tivity analyses, from either perspective the QIV/Q-LAIV
100 % scenario remained the policy with the highest
expected net benefit at cost-effectiveness thresholds above
€15,000/QALY. Use of frequency-dependent mixing did
not qualitatively change the cost effectiveness of the sce-
narios. See the electronic supplementary results for more
detail.
4 Discussion
This study assessed the net health gains within the Finland
population of a policy decision to switch from using
trivalent to quadrivalent seasonal influenza vaccines. Such
a switch is estimated to reduce the incidence of influenza-
related disease, prevent deaths and save healthcare
resources.
On average, a switch from trivalent inactivated to QIVs
was estimated to result in an 11 % reduction in the average
annual number of symptomatic infections, leading to a
corresponding 13–16 % reduction in expected cases of
medically attended influenza. Influenza-related deaths were
estimated to fall by approximately 18 % (an average of 54
lives saved per year).
The use of the live attenuated vaccine in children, with
its higher efficacy, nearly doubled the average annual
number of symptomatic infections and GP consultations
averted by switching from TIV to quadrivalent vaccine,
while saving a further 47 and 33 % of influenza-related
hospitalisations and deaths, respectively. As most hospi-
talisations and deaths are in the elderly, a group not indi-
cated for vaccination with Q-LAIV, the majority of these
latter savings arise as a result of herd protection.
Considerable uncertainty exists in quantifying many of
the processes involved in estimating the epidemiological,
clinical and economic impact of switching from trivalent to
quadrivalent influenza vaccination.
This study applied a full PSA encompassing the uncer-
tainty in both the transmission dynamics of influenza and
the clinical and economic inputs to a model of influenza
vaccination. As such, it takes a more thorough account of
parameter uncertainty than previous studies of the potential
impact of a change in influenza vaccination practice
[11, 12, 21, 37–39].
Fig. 5 Discounted incremental costs (2014 Euros) and QALYS of
five vaccination scenarios compared with the no vaccination scenario.
Bars represent the range in which 95 % of simulations fell. Scenario
names in the key are defined in Table 3. QALYs quality-adjusted life-
years, TIV trivalent inactivated vaccine, QIV quadrivalent inactivated
vaccine, Q-LAIV quadrivalent live-attenuated influenza vaccine
Quadrivalent versus trivalent influenza vaccination in Finland 947
The PSA, with its method of sampling the transmission
parameter distributions and accepting those that fit to the
observed paediatric incidence, led to a group of 8998
parameter sets that together form the calibrated model. In
the high-dimensional parameter space of this transmission
model, there is a danger that fitting routines may be stuck
in a local minimum, and no guarantee that any minimum
found corresponds to the real-world situation; these limi-
tations are avoided by our method, which samples across
parameter space. While a parameter set exists that provides
the best fit (lowest deviance) compared with the data [22]
calibrated over the 2000–2002 influenza seasons, there is
no specific parameter set that will yield the average model
results, or yield best-fitting results over an extended time
period. However, as shown in Fig. 2, the aggregate model
behaviour closely encompasses the observed Finnish inci-
dence of influenza.
As is evident from the univariate sensitivity analysis, the
most influential parameters are those that are key drivers of the
transmission dynamics. Despite the uncertainty surrounding
the magnitude and shape of the input distributions for the
parameters that determine R0, clear unimodal parameter dis-
tributions were obtained for the basic reproductive number,
with mean values for each subtype and lineage falling between
1.5 and 2.2, consistent with previous estimates [40, 41].
Vaccination was implemented in a pulse prior to the
start of the season. This was a limitation as it did not take
account of the ramp-up time required to reach a particular
level of coverage, and therefore over estimated the person
days spent protected in any one season. Univariate analyses
Fig. 6 CEACs and CEAFs for the scenarios presented in Sect. 2.3.1,
both including all calculated costs and with productivity costs
excluded. Scenario names in the key are defined in Table 3. ENB
expected net benefit. CEAC cost-effectiveness acceptability curve,
CEAF cost-effectiveness acceptability frontier, QALY quality-ad-
justed life-year, TIV trivalent inactivated vaccine, QIV quadrivalent
inactivated vaccine, Q-LAIV quadrivalent live-attenuated influenza
vaccine
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showed the uptake level had a moderate effect on the
model outcomes.
The survey of vaccine uptake, conducted as part of this
study, revealed that vaccine coverage in children over
36 months, not currently recommended for vaccination,
was comparable with and possibly higher (22–28 %) than
in children under 4 years of age (23 %), reflecting the
mixed private/public nature of healthcare in Finland. These
higher rates are possibly because individuals with relatives
in an at-risk group are also indicated for free vaccination
[42], and therefore may have been vaccinated for the sake
of those relatives. Despite this observation, paediatric
coverage is below that seen in some other countries,
notably the US, where vaccine uptake in children has
exceeded 50 % since 2010 [43]. If vaccine uptake in
children were to increase, then it is likely that even greater
reductions in influenza-related disease could be achieved.
This is particularly true for policies involving the use of
quadrivalent vaccines, where the effect of higher uptake is
not diluted by periodic mismatching between the influenza
B lineage used for the vaccine and that circulating in the
population.
A lack of seroepidemiological data from Finland means
that it is not possible to directly validate the model’s
simulated incidence of infection, independent of symp-
tomatic presentation. The probability of symptoms, given
an influenza infection, are however based on a meta-anal-
ysis of challenge studies [44]. Although these challenge
studies were conducted exclusively in young adults, the
subsequent correspondence achieved in the temporal pat-
tern of average annual symptomatic disease incidence
between the model and surveillance data published by THL
is reassuring, particularly as the THL data were not used in
the calibration process and the simulated incidence of
symptomatic infection is highly sensitive to the probability
of an infection being symptomatic.
No previous studies exist of the cost effectiveness of
introducing quadrivalent influenza vaccination in Finland;
however, published studies exist from elsewhere, including
the US [11, 14], Canada [15] and the UK [15, 37]. In
contrast with the dynamic model used in this paper, two of
these studies [11, 37] use static models and will therefore
underestimate the number of clinical events averted by
vaccination and hence undervalue quadrivalent vaccina-
tion. All three studies estimate quadrivalent vaccination to
be cost effective. Differences in population size, density
and pre-existing immunity due to historical influenza
transmission and vaccination coverage mean that the
underlying transmission dynamics of influenza are likely to
differ between these countries. This, together with different
model structures, makes it difficult to directly compare
estimates of averted costs and QALYs across studies.
While parameter uncertainty has been thoroughly
explored in a PSA on the transmission as well as clinical
and economic parameters, this has been undertaken within
the constraints imposed by the structure of the model. The
structural assumptions made by the current dynamic
transmission model have been previously published
[16, 21, 38] and are outlined in detail in the electronic
supplementary material. One of these assumptions is a lack
of cross-protection between different lineages of influenza
B. Recent analyses have suggested that some degree of
cross-protection may exist [36, 45, 46], the consequence of
which would be to reduce the incremental benefit of
quadrivalent vaccines over their trivalent counterparts. The
magnitude of this cross-protection remains unclear, with
estimates ranging from 0 to 60 %.
5 Conclusions
This analysis demonstrates that quadrivalent vaccination is
likely to be highly cost effective. From a societal perspective,
of those scenarios examined, the use of Q-LAIV in children
aged 2 to\18 years of age, and QIV in all other age groups,
had the highest probability of being cost effective at all cost-
effectiveness thresholds, and yielded the highest ENHB. If
productivity costs are excluded, from a payer perspective this
scenario has the highest ENHB at cost-effectiveness thresh-
olds above €6000/QALY. A switch to such a policy is likely
to be highly cost effective, reducing the burden of influenza-
related disease and freeing up healthcare resources.
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